Q&A Would you deny BTK inhibitor therapy to a Waldenström’s macroglobulinemia patient who is wild-type for MYD88 and CXCR4 genes?

 VIDEO   00:01:10   07/2021

The expert panel answers questions from the audience on a range of topics related to Waldenström’s macroglobulinemia diagnosis and treatment selection.

Rating

Rate this resource